

Title (en)
MEANS AND METHODS FOR MONITORING ANTIRETROVIRAL THERAPY AND GUIDING THERAPEUTIC DECISIONS IN THE TREATMENT OF HIV/AIDS

Title (de)
VORRICHTUNGEN UND METHODEN ZUR UEBERWACHUNG VON ANTIRETROVIRALER THERAPIE UND ZUR HINFÜHRUNG ZU THERAPEUTISCHEN ENTSCHEIDUNGEN BEI DER BEHANDLUNG VON HIV/AIDS

Title (fr)
SYSTEMES ET PROCEDES POUR LE CONTROLE DE THERAPIE ANTIRETROVIRALE ET L'ORIENTATION DES DECISIONS THERAPEUTIQUES DANS LE TRAITEMENT DU VIH/SIDA

Publication
EP 1292712 A4 20050420 (EN)

Application
EP 01944452 A 20010612

Priority
• US 0118882 W 20010612
• US 59189400 A 20000612

Abstract (en)
[origin: WO0196611A1] This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS) and further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy, particularly nucleoside reverse transcriptase inhibitor therapy using phenotypic susceptibility assays or genotypic assays.

IPC 1-7
C12Q 1/70

IPC 8 full level
C12N 15/09 (2006.01); **A61K 45/00** (2006.01); **A61P 31/18** (2006.01); **C07K 14/16** (2006.01); **C12N 15/867** (2006.01); **C12Q 1/02** (2006.01); **C12Q 1/68** (2006.01); **C12Q 1/70** (2006.01)

CPC (source: EP)
A61P 31/18 (2017.12); **C07K 14/005** (2013.01); **C12N 15/86** (2013.01); **C12Q 1/703** (2013.01); **C12N 2740/16043** (2013.01); **C12N 2740/16122** (2013.01)

Citation (search report)
• [X] WO 9961658 A1 19991202 - VIROLOGIC INC [US]
• [Y] WO 9727332 A1 19970731 - INNOGENETICS NV [BE], et al
• [Y] WO 9727480 A1 19970731 - VIRCO NV [BE], et al
• [Y] CLERCQ DE E: "DEVELOPMENT OF RESISTANCE OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) TO ANTI-HIV AGENTS: HOW TO PREVENT THE PROBLEM?", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, AMSTERDAM, NL, vol. 9, no. 1, 1997, pages 21 - 36, XP000878561, ISSN: 0924-8579
• [Y] SALOMON H ET AL: "Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.", AIDS (LONDON, ENGLAND) 28 JAN 2000, vol. 14, no. 2, 28 January 2000 (2000-01-28), pages F17 - F23, XP008037438, ISSN: 0269-9370
• [Y] MELLORS J W ET AL: "MUTATIONS IN HIV-1 REVERSE TRANSCRIPTASE AND PROTEASE ASSOCIATED WITH DRUG RESISTANCE", INTERNATIONAL ANTIVIRAL NEWS, CHURCHILL LIVINGSTONE, EDINBURGH, GB, vol. 3, 1995, pages 8 - 13, XP000614717, ISSN: 0965-2310
• [Y] HOLODNIY M ET AL: "Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy.", JOURNAL OF VIROLOGY. JUN 1995, vol. 69, no. 6, June 1995 (1995-06-01), pages 3510 - 3516, XP002317435, ISSN: 0022-538X
• [Y] PELEMANS H ET AL: "CHARACTERISTICS OF THE PRO225HIS MUTATION IN HUMAN IMMUNODEFICIENCYVIRUS TYPE 1 (HIV-1) REVERSE TRANSCRIPTASE THAT APPEARS UNDER SELECTIVE PRESSURE OF DOSE-ESCALATING QUINOXALINE TREATMENT OF HIV-1", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 71, no. 11, November 1997 (1997-11-01), pages 8195 - 8203, XP000885693, ISSN: 0022-538X
• [A] KANKI P J ET AL: "VIROLOGY OF HIV-1 AND HIV-2: IMPLICATIONS FOR AFRICA", AIDS, LONDON, GB, vol. 11, no. SUPPL B, 1997, pages S33 - S42, XP008035289, ISSN: 0269-9370
• See references of WO 0196611A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)
WO 0196611 A1 20011220; AU 6686301 A 20011224; BR 0111575 A 20030624; CA 2411401 A1 20011220; CN 1446265 A 20031001; EP 1292712 A1 20030319; EP 1292712 A4 20050420; JP 2004503253 A 20040205; ZA 200210003 B 20041222

DOCDB simple family (application)
US 0118882 W 20010612; AU 6686301 A 20010612; BR 0111575 A 20010612; CA 2411401 A 20010612; CN 01814056 A 20010612; EP 01944452 A 20010612; JP 2002510724 A 20010612; ZA 200210003 A 20021210